Abstract 3193: Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51 | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Abstract 3193: Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51

Cancer Res (2017) 77 (13_Supplement): 3193.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Sacituzumab govitecan: past, present and future of a new antibody–drug conjugate and future horizon

Jenny Furlanetto
Frederik Marmé
Sibylle Loibl

Future Oncology (2022) 18 (28): 3199.

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy

Jae Ho Jeong
Sung-Bae Kim

The Breast (2022) 66: 199.

Sacituzumab Govitecan: First Approval

Yahiya Y. Syed

Drugs (2020) 80 (10): 1019.

Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy

David M. Goldenberg
Robert M. Sharkey

Expert Opinion on Biological Therapy (2020) 20 (8): 871.

Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan

David M. Goldenberg
Robert M. Sharkey

mAbs (2019) 11 (6): 987.

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

David M. Goldenberg
Rhona Stein
Robert M. Sharkey

Oncotarget (2018) 9 (48): 28989.